A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.

A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.

Epitopes that are conserved among SARS-like coronaviruses are attractive targets for design of cross-reactive vaccines and therapeutics. CR3022 is a SARS-CoV neutralizing antibody to a highly conserved epitope on the receptor binding domain (RBD) on the spike protein that is able to cross-react with...

Full description

Bibliographic Details
Main Authors: Nicholas C Wu, Meng Yuan, Sandhya Bangaru, Deli Huang, Xueyong Zhu, Chang-Chun D Lee, Hannah L Turner, Linghang Peng, Linlin Yang, Dennis R Burton, David Nemazee, Andrew B Ward, Ian A Wilson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-12-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009089

Internet

https://doi.org/10.1371/journal.ppat.1009089

Similar Items